An additional 94 new drugs, including two to support patients living with diabetes, are now covered under Manitoba’s pharmacare program.
“When people are living with a chronic condition like diabetes, it can be a challenge to cover medication costs,” health minister Sharon Blady said in a release. “Adding these new drugs to the formulary will help Manitoba families address those costs and let them focus on other priorities as they receive the care they need.”
Two of the new drugs being added to the formulary are Komboglyze and Levemir, which are used for the treatment of diabetes.
“We commend the Manitoba government for its decision to expand the medications covered by the pharmacare program. This is great news for people living with diabetes in Manitoba,” Andrea Kwasnicki, Manitoba regional director for the Canadian Diabetes Association, said. “By expanding pharmacare, people living with diabetes and their health-care providers will now have additional choices to help better manage their diabetes.”
Some of the other new drugs added to the formulary include Aubagio, for the treatment of multiple sclerosis; Esbriet, for the treatment of idiopathic pulmonary fibrosis; Galexos, for the treatment of Hepatitis C; Invega Sustenna, for the treatment of schizophrenia; Stivarga, for the treatment of gastrointestinal stromal tumors; TOBI Podhaler, for the treatment of cystic fibrosis; Actemra, for the treatment of polyarticular juvenile rheumatoid arthritis; and a new strength of Xeomin, for the treatment of uncontrolled twitching of the neck and eye muscles.
Of the 94 drugs added, 80 are generic medications. The minister noted these additions are expected to save Manitoba families $3.9 million a year and coverage for the new drugs.
Over the last 12 years, approximately 4,000 new drugs, including those that treat cystic fibrosis, lung cancer, pulmonary embolism and schizophrenia, have been added to Manitoba’s world-class pharmacare program, minister Blady said.